Change in Palliative Performance Scale (PPS) Predicts Survival in Patients with Terminal Cancer

Oh, Jung Hyub; Lee, Yong Joo; Seo, Min Seok; Yoon, Jo Hi; Kim, Chul Min; Kang, Chung Jan

doi:10.14475/kjhpc.2017.20.4.235

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study among hospitalized patients with terminal cancer identified a score change of >30% yielded a HR for death of 2.66 (95% CI: 2.19-3.22) compared to a score change of ≤30% [23]. A PPS score of ≤30 was also independently predictive of survival with a HR of 1.67 (95% CI: 1.30-2.02) compared to a PPS score >30 [28]. Where our investigation noted a single PPS score at the time of admission, changes in PPS may be a more sensitive indicator of death.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Benzodiazepine Use and Morbidity-Mortality Outcomes in a Geriatric Palliative Care Unit: A Retrospective Review

Senderovich

Gardner

Berall

et al. 2021

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Introduction: Patients often experience delirium at the end of life. Benzodiazepine use may be associated with an increased risk of developing delirium. Alternate medications used in conjunction with benzodiazepines may serve as an independent precipitant of delirium. The aim is to understand the role of benzodiazepines in precipitating delirium and advanced mortality in palliative care population at the end of life. Methods: A retrospective medical chart review was conducted at a hospice and palliative care inpatient unit between the periods of June 2017–December 2017 and October 2017–November 2018. It included patients in hospice and palliative care inpatient units who received a benzodiazepine and those who did not. Patient characteristics, as well as Palliative Performance Scale score, diagnosis, and occurrence of admission, terminal, and/or recurrent delirium, were collected and analyzed. Results: Use of a benzodiazepine was not significantly associated with overall mortality nor cause-specific death without terminal delirium rate. However, it was significantly associated with higher cause-specific death with terminal delirium rate and a higher recurrent delirium rate. Discussion: This retrospective chart review suggests an association between benzodiazepine use and specific states of delirium and cause-specific death. However, it does not provide strong evidence on the use of this drug, especially at the end of life, as it pertains to the overall mortality rate. Suggested is a contextual approach to the use of benzodiazepines and the need to consider Palliative Performance Scale score and goals of care in the administration of this drug at varying periods during patient length of stay.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%